Alternative to tissue-based
biopsies, for when tissue
can be difficult to extract

LiquidGx™ is a non-invasive cancer test
for selecting relevant solid tumor therapies

Sample Report
Sample Report
Information Sheet
Information Sheet
LiquidGx_tm LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_iocn1 LiquidGx
Established guidelines recommend liquid biopsy when tissue biopsy is not feasible
LiquidGX_iocn2 LiquidGx
Utilizes proprietary technology to analyze ctDNA/RNA to accurately detect cancer-driving mutations
LiquidGX_iocn3 LiquidGx
Measures actionable mutations from blood for the selection of solid tumor targeted treatment
LiquidGX_iocn4 LiquidGx
Testing at multiple time points allows quantitative monitoring for drug resistance markers
LiquidGx_tm-e1528984431305 LiquidGx
A non-invasive cancer test that can easily become part of your workflow
LiquidGX_iocn1-e1528984817362 LiquidGx

Established guidelines
recommend liquid biopsy
when tissue biopsy is not
feasible

LiquidGX_iocn2-e1528984831396 LiquidGx

Utilizes proprietary
technology to analyze
ctDNA/RNA to accurately
detect cancer-driving
mutations

LiquidGX_iocn3-e1528984868182 LiquidGx

Measures actionable
mutations from blood for
the selection of solid tumor
targeted treatment

LiquidGX_iocn4-e1528984886741 LiquidGx

Testing at multiple time
points allows
quantitative monitoring
for drug resistance
markers

MSI Status for PD-1 Immune
Checkpoint Inhibitors

In addition to actionable mutations for targeted therapy, LiquidGx™ provides microsatellite instability (MSI) status. MSI status can predict a predisposition to mutations as a result from impaired DNA mismatch repair (MMR) and help predict if a tumor will respond to anti-PD-1 therapy.

MSI status is determined by detecting the length of mononucleotide repeats at five genomic sites (BAT-25, BAT-26, NR-21, NR-24, and NR-27)

Tumor-Specific_DNA_Slippage_events LiquidGx

A shift in repeat length(formation of a second peak) observed in the cell-free DNA (cfDNA) compared to genomic DNA (gDNA) at 2 or more sites indicates MSI-High

Inactive_Cytotoxic_T-CellTumor_Cell LiquidGx

T-cell cannot recognize tumor cell as foreign

Inactive_Cytotoxic_T-CellTumor_Cell_Antibody LiquidGx

With anti-PD1 therapy, T-Cell can now recognize tumor cell as foreign

Clear, Color-Coded Results

Same_Tumor_Type_icon_green LiquidGx

Therapies with Potential Clinical Benefit
SAME TUMOR TYPE

Recommends FDA-approved drugs for
that indication

Different_Tumor_Type_icon_blue LiquidGx

Therapies with Potential Clinical Benefit
DIFFERENT TUMOR TYPE

FDA-approved drugs for other indications
that may be beneficial

Lack_of_clinical_benefit_icon LiquidGx

Lack of Clinical Benefit
SAME TUMOR TYPE

Drugs that will likely not show any benefit
due to the presence of resistant markers

clinical_trials_icon_purple LiquidGx

Clinical Trials
to Consider

For each variant found, will provide up to 5
relevant clinical trials with geographic
considerations

Download Sample Report

Two Platforms Available:

qPCR

ALKBRAFEGFRKRAS
  • Single gene analytes via qPCR that can be run individually or multiplexed

  • Offers accurate results within 3 business days so results can be in-hand before a patient’s first oncology consultation

  • Limit-of-detection 0.01%, the equivalent of finding one DNA fragment in 10,000

  • Optimal fusion detection via ctRNA

NGS

AKT1ALKBRAFEGFRERBB2HRAS
KITKRASMAP2K1METNRASPDGFRA
PIK3CAPTENRETROS1TP53
  • Next Generation Sequencing test, coverage of >170 variants in 17 genes frequently mutated in cancer

  • Turnaround time of 3-5 business days, which is faster than standard protocols including reflexive FISH and immunohistochemistry testing

  • Includes MSI for selection of anti-PD1 therapy

  • Limit-of-detection 0.1% (SNV, fusion), 2% (MSI), 2.5 total gene copies (CNV)

  • Input includes both ctDNA and ctRNA allowing for optimal fusion detection including, novel fusions

Both platforms include:

EGFR T790M and EGFR C797S variant detection for drug resistance monitoring

LiquidGx™ NGS quantifiable detects variants – producing actionable results

   Also detectable by qPCR   

GenesVariantsPotential Treatment Implications
AKT1E17KMay benefit from treatment with temsirolimus and everolimus
ALK Fusions: EML4, KIF5B, TFG, STRNMay benefit from treatment with crizotinib, ceritinib, or alectinib
L1196M, G1202R, I1171T/N/S, F1174L/S, E1210K, 1151Tins, C1156Y,L1198F,V1190L, D1203N, S1206Y/C, G1269APredictive of crizotinib resistance. May demonstrate benefit with ceritinib, alectinib, and brigatinib
BRAF V600E, V600K, V600D, V600G, V600M, V600RMay benefit from treatment with
vemurafenib, dabrafenib,
vemurafenib + cibimetinib, or
dabrafenib + trametinib
L597R, L597Q,L597S, L597V, D594G, D594VMay result in clinical trial recommendations
EGFR L858R, E746_A750del, E746_A750delELREA, G719A, G719C, G719S, E746_S752delinsA, A763_Y7g4insFQEA, K745_A750del, L747_S752del, additional Exon19_delMay benefit from treatment with gefitinib, erlotinib, or afatinib
Exon20_insMay demonstrate lack of clinical benefit to gefitinib and erlotinib
 T790MMay benefit from treatment with osimertinib if previously treated with 1st or 2nd generation EGFR-TKIs
 C797SMay demonstrate acquired resistance to osimertinib
CNVMay benefit from treatment with gefitinib, erlotinib, or afatinib
ERBB2Exon20_ins, G776L, G776_777insVCMay benefit from treatment with trastuzumab and afatinib
CNVMay benefit from treatment with trastuzumab and lapatinib
HRASG12R, G12V, G13R, G13R, Q61RMay benefit from treatment with MEK inhibitors
KRAS G12C, G12V, G12D, G12A, G12R, G12S,
G13D, G13D,
G13A, G13R, G13S, G13V,
K117N, A146P, A146T, A146V,
Q61H, Q61K, Q61L, Q61P, Q61R
Often associated with poor prognosis including resistance to gefitinib, erlotinib, cetuximab, panitumumab
KITK642E, Exon_11 SNVsMay benefit from treatment with imatinib, nilotinib, sunitinib, and sorafenib
MAP2K1C121S, P124S, P124LMay result in clinical trial recommendations
METCNVMay benefit from treatment with crizotinib, erlotininb, and gifitinib
Exon14_skippingMay benefit from treatment with crizotinib
NRASG12C, G12R, G12W, G12A, G12D, G12VOften associated with poor prognosis including resistance to gefitinib, erlotinib, cetuximab, panitumumab
G13C, G13R, G13A, G13D, G13VMay benefit from treatment with sorafenib
Q61K, Q61R, Q61L, Q61H, Q61E, Q61POften associated with resistance to gefitinib, erlotinib, cetuximab, and panitumumab but may benefit from sorafenib
PIK3CAE542K, E545K, H1047RMay benefit from treatment with temsirolimus and everolimus
PDGFRAD842VOften associated with resistance to imatinib and sunitinib
PTENR130*, R130G, R130Q, R130P, R130L, R233*, K267*, T319*May result in clinical trial recommendations
RETM918T, C634R, C634Y, C634WMay benefit from treatment with vandetanib
Fusions: CCDC6, NCOA4, KIF5BMay benefit from treatment with vandetanib and cabozantinib
ROS1Fusions: LRIG3, TPM3, EZR, SDC4, GOPC, SLC34A2, CD74May benefit from treatment with crizotinib
TP53R175H, G245S, R248Q, R248W, R249S, R273H, R2473C, R2482WMay result in clinical trial recommendations
MSI StatusMononucleotides: BAT-25, BAT-26, NR-21, NR-24, and NR-27May benefit from treatment with pembrolizumab and nivolumab

LiquidGx™ complements Admera Health’s suite of molecular diagnostics:

oncogxselect LiquidGx

Solid tumor profiling for
targeted therapy selection
following established guidelines

Learn more
oncogxone LiquidGx

Comprehensive solid tumor
profiling for targeted therapy
selection

Learn more
pgxonco LiquidGx

Genetic testing for optimizing supportive care drug therapy for cancer patients

Learn more